Any current/future new fundraising through debt or equity?

No current or future fundraising plans through debt or equity. The INR18 crores capex done in the last year was funded entirely from internal cash accruals. The company is currently debt-free with a positive net cash position of over INR3 crores. Management indicated no need for major capital expenditure over the next 2-3 years that would require external funding. Emphasis on leveraging internal resources and cash flows to fund growth and expansion.

Any current/future capex/capital investment/strategic investment?

Major expansion is behind, but continuous capital investment will occur for maintenance, adding instruments, and minor expansions (e.g., AHU additions). (Page 16) No large new facility expansions planned for next 2-3 years to achieve targets; mainly internal capex and maintenance ongoing. (Page 12, 16) Dermatology manufacturing setup planned within next 2 years with estimated capex around INR 20 crores, funded through internal cash flows. (Page 14) Last year internal capex was around INR 18 crores distributed among three companies; no external fund raising planned as investments are from

Future growth expectations in sales/revenue/volumes?

Beta Drugs Limited targets a continuous growth rate of 25%-30% CAGR over the next 2-3 years, maintaining the current trajectory. By FY ‘25 and FY ‘26, major growth drivers will be exports, own brand sales, and API business. The company plans to double sales in the next three years, targeting INR450 crores revenues. Export business growth is fueled by approvals and regulatory clearances in multiple countries. Own brands are expected to contribute around INR140-150 crores in sales within three years. The CDMO business will grow steadily at 10%-12%. Dermatology segment aims to reach break-even so

Future growth expectations in earnings/operating earnings/profits/EPS?

Beta Drugs targets a 25%-30% consistent growth over the next 2-3 years, maintaining the trajectory of prior years. EBITDA margins are expected to cross around 25%-26%, with potential for even higher margins if conditions improve. Major growth drivers include export business, own brands (targeting INR140-150 crores in next three years), and API business both domestically and internationally. CDMO business expected to grow steadily at about 10%-15%, aligned with oncology market CAGR. Gross margins have improved significantly due to backward integration and innovation, from 39% to 43%. The compan

Current/ Expected Orderbook/ Pending Orders?

Beta Drugs Limited has secured partners in 12-15 Latin American countries, including Mexico and Colombia, and has completed business development activities there. The company has started receiving API export orders from countries like Algeria, Pakistan, Bangladesh, and Russia, with expectations of exporting to three to four countries in the next 1-1.5 months. The expected revenue from API exports for the current year is around INR 3 to 4 crores. The company is actively working on obtaining multiple regulatory approvals (such as Europe, Eurasia, and ANVISA) to expand its international exports a

Beta Drugs LtdQ4 FY23Pharmaceuticals & Biotechnology

Beta Drugs Ltd Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,849.7P/E: 45.0Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Beta Drugs Limited targets a continuous growth rate of 25%-30% CAGR over the next 2-3 years, maintaining the current trajectory.
By FY ‘25 and FY ‘26, major growth drivers will be exports, own brand sales, and API business.
The company plans to double sales in the next three years, targeting INR450 crores revenues.
Export business growth is fueled by approvals and regulatory clearances in multiple countries.
Own brands are expected to contribute around INR140-150 crores in sales within three years.
The CDMO business will grow steadily at 10%-12%.
Dermatology segment aims to reach break-even soon and grow significantly in 3-4 years.
EBITDA margins targeted to remain around 25%-26%, with potential upside.
Management sees minimal risk factors; growth is supported by increased capacities and experienced young leadership.

Margin guidance

Category 3

Beta Drugs targets a 25%-30% consistent growth over the next 2-3 years, maintaining the trajectory of prior years.
EBITDA margins are expected to cross around 25%-26%, with potential for even higher margins if conditions improve.
Major growth drivers include export business, own brands (targeting INR140-150 crores in next three years), and API business both domestically and internationally.
CDMO business expected to grow steadily at about 10%-15%, aligned with oncology market CAGR.
Gross margins have improved significantly due to backward integration and innovation, from 39% to 43%.
The company expects EBITDA and net profit to grow proportionally with revenue, supported by increased production capacity and new products.
Employee costs and marketing expenses will rise but remain well-controlled relative to revenue growth.
No major capex planned beyond internal maintenance and minor expansions, helping profitability remain stable.
Management expresses confidence in achieving targets without major hurdles, emphasizing disciplined execution.

See what Beta Drugs Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No current or future fundraising plans through debt or equity.
The INR18 crores capex done in the last year was funded entirely from internal cash accruals.
The company is currently debt-free with a positive net cash position of over INR3 crores.
Management indicated no need for major capital expenditure over the next 2-3 years that would require external funding.
Emphasis on leveraging internal resources and cash flows to fund growth and expansion.

Order book

Beta Drugs Limited has secured partners in 12-15 Latin American countries, including Mexico and Colombia, and has completed business development activities there.
The company has started receiving API export orders from countries like Algeria, Pakistan, Bangladesh, and Russia, with expectations of exporting to three to four countries in the next 1-1.5 months.
The expected revenue from API exports for the current year is around INR 3 to 4 crores.
The company is actively working on obtaining multiple regulatory approvals (such as Europe, Eurasia, and ANVISA) to expand its international exports and is targeting significant growth from these markets.
They anticipate rapid growth from oncology-focused new drug delivery systems (NDDS) slated for launch in the next 1.5 years.
Overall growth targets include doubling sales by FY ‘25-‘26, with major contributions expected from own brand sales, exports, and API business.

See what Beta Drugs Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Major expansion is behind, but continuous capital investment will occur for maintenance, adding instruments, and minor expansions (e.g., AHU additions). (Page 16)
No large new facility expansions planned for next 2-3 years to achieve targets; mainly internal capex and maintenance ongoing. (Page 12, 16)
Dermatology manufacturing setup planned within next 2 years with estimated capex around INR 20 crores, funded through internal cash flows. (Page 14)
Last year internal capex was around INR 18 crores distributed among three companies; no external fund raising planned as investments are from internal accruals. (Page 12)
Continuous process of minor capital additions expected as per evolving needs but no major new capex announced currently. (Page 16)

Track Beta Drugs Ltd — get its next earnings analysis in your feed

How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisBeta Drugs Ltd

Rev 2Mar 3

See where Beta Drugs Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Beta Drugs Ltd rank in Pharmaceuticals & Biotechnology?

Compare Beta Drugs Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Beta Drugs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →